Home
HelpRivaroxaban Level
eD-H Order Code
LAB4047
Specimen Collection Information
| Specimen | Minimum Test Volume | Container | Special Handling |
|---|---|---|---|
Blood |
Neonatal/Pediatric All other Coag tubes must be filled to the line on tube. |
Specimen Transport Temperature
Double spin, separate, and freeze
Specimen Stability
4 hours
Additional Specimen Instructions
1.8 mL Sodium Citrate tube filled to the line
OR
2.7 mL Sodium Citrate tube filled to the line
Blue top tubes must be filled within 10% of stated volume. A discard tube must be used if a citrate tube is to be drawn using a winged blood collection set. It is important to remove air from the blood collection set to ensure the proper blood volume is obtained in the coag tube.
If the patient has a known hematocrit >55%, please contact the coagulation lab for an adjusted collection tube before drawing the blood.
Interpretive Data
| Assay Display | Interpretive Data |
|---|---|
| Rivaroxaban Level |
Rivaroxaban an oral anticoagulant that directly inhibits factor Xa has been approved by the US Food and Drug Administration for prophylaxis of thrombosis in atrial fibrillation and surgical patients and treatment of venous thromboembolism (VTE). Unlike warfarin it does not require routine therapeutic monitoring. However in selected clinical situations measurement of drug level would be useful (eg kidney insufficiency assessment of compliance periprocedural measurement of drug concentration suspected overdose advanced age and extremes of body weight). Therapeutic reference ranges have not been established however peak and trough levels observed in clinical trials at different dosing are available. Rivaroxaban concentrations may be affected by drug interactions and liver or kidney disease. |
Patient population/Clinical Rivaroxaban Trough Plasma Peak Plasma
setting dose Concentration Concentration
ng/mL ng/mL
(predose)* (postdose)**
VTE prevention after total 10 mg once 1 - 38 91 - 196
hip replacement surgery daily
DVT treatment (continue 20 mg once 6 - 87 189 - 419
treatment) daily
Stroke prevention in patients 20 mg once 12 - 137 184 - 343
with non-valvular atrial daily
fibrillation
(CrCl >/=50 mL/min)
Stroke prevention in patients 15 mg once 18 - 136 178 - 313
with non-valvular atrial daily
fibrillation
(CrCl 30 - 49 mL/min)
Secondary prevention 2.5 mg twice 6 - 37 28 - 70
in patients with acute daily
coronary syndrome
*Defined as samples collected 20-28 hours after dosing
**Defined as samples collected 2-4 hours after dosing
CPT(s)
80299
Performing Lab Section
Hematology